FibroGen Enters Material Definitive Agreement

TL;DR

FibroGen just signed a big deal, filing an 8-K on Aug 12th.

AI Summary

FibroGen, Inc. entered into a Material Definitive Agreement on August 12, 2025. The company, headquartered in San Francisco, CA, filed an 8-K report detailing this agreement. The filing also includes financial statements and exhibits related to the agreement.

Why It Matters

This filing indicates a significant new contract or partnership for FibroGen, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry significant risks and rewards, depending on the nature and terms of the agreement.

Key Players & Entities

• FibroGen, Inc. (company) — Registrant
• August 12, 2025 (date) — Date of earliest event reported
• 350 Bay Street Suite 100 #6009 San Francisco, California 94133 (address) — Principal Executive Offices
• 415-978-1200 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
• $18.75 million — n the United States by the Company from $18.75 million to $15 million. The foregoing descrip
• $15 million — s by the Company from $18.75 million to $15 million. The foregoing description of the Fou

Filing Documents

• fgen-20250812.htm (8-K) — 47KB
• fgen-ex10_1.htm (EX-10.1) — 60KB
• 0000950170-25-108280.txt ( ) — 216KB
• fgen-20250812.xsd (EX-101.SCH) — 24KB
• fgen-20250812_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 12, 2025, FibroGen entered into the fourth amendment ("Fourth Amendment") to the financing agreement, dated as of April 29, 2023 as amended ("Financing Agreement") with investment funds managed by Morgan Stanley Tactical Value, as lenders (the "Lenders") and Wilmington Trust National Association, as administrative agent for the Lenders (the "Administrative Agent"), as previously amended. The Fourth Amendment further reduces the minimum qualified cash balance required to be held in deposit accounts or securities accounts in the United States by the Company from $18.75 million to $15 million. The foregoing description of the Fourth Amendment to the Financing Agreement is not complete and is qualified in its entirety by reference to the full text of the Fourth Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Fourth Amendment to Financing Agreement by and among FibroGen, Inc., NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II ESC Fairview Holding LLC, and Wilmington Trust, National Association, dated as of August 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. FibroGen, Inc. Date: August 13, 2025 By: /s/ John Alden John Alden General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR